Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation

Abstract The efficacy of sustained-release preparations of mesalazine as a remission maintenance treatment for Crohn's disease remains to be established. We aimed to examine the changes in compliance rate and clinical data 2 years after switching from mesalazine tablet to granule formulation at...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Satoshi Tamura, Natsuki Ishida, Takahiro Miyazu, Shunya Onoue, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/51034e09db5b4b42b964b2e511743e39
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:51034e09db5b4b42b964b2e511743e39
record_format	dspace
spelling	oai:doaj.org-article:51034e09db5b4b42b964b2e511743e392021-12-02T16:09:09ZMesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation10.1038/s41598-020-78603-92045-2322https://doaj.org/article/51034e09db5b4b42b964b2e511743e392020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78603-9https://doaj.org/toc/2045-2322Abstract The efficacy of sustained-release preparations of mesalazine as a remission maintenance treatment for Crohn's disease remains to be established. We aimed to examine the changes in compliance rate and clinical data 2 years after switching from mesalazine tablet to granule formulation at our facility among patients with Crohn's disease in remission. We investigated the rate of continuous treatment of mesalazine granules and examined the changes in Crohn’s Disease Activity Index (CDAI) and serum C-reactive protein (CRP), albumin, and hemoglobin (Hb) levels 2 years after the switch. Compliance rate (continuous treatment vs. additional treatment) and continuous treatment rate [good (rate of ≥ 70%) vs. poor (rate < 70%)] were investigated. Of 46 patients, 12 (27.3%) received additional treatment and 32 (72.7%) did not require additional treatment in 2 years. No significant change in CDAI after switching to granule modification was noted in 32 patients in the continuous treatment group. Nevertheless, clinical remission was maintained for 2 years, and serum CRP levels decreased significantly (P = 0.023) and Hb levels increased significantly (P = 0.002). No change in the compliance rate was found. Our results suggest that mesalazine granule formulation may have a remission maintenance effect that is superior to that of mesalazine tablets.Satoshi TamuraNatsuki IshidaTakahiro MiyazuShunya OnoueShinya TaniMihoko YamadeYasushi HamayaMoriya IwaizumiSatoshi OsawaTakahisa FurutaKen SugimotoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Satoshi Tamura Natsuki Ishida Takahiro Miyazu Shunya Onoue Shinya Tani Mihoko Yamade Yasushi Hamaya Moriya Iwaizumi Satoshi Osawa Takahisa Furuta Ken Sugimoto Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
description	Abstract The efficacy of sustained-release preparations of mesalazine as a remission maintenance treatment for Crohn's disease remains to be established. We aimed to examine the changes in compliance rate and clinical data 2 years after switching from mesalazine tablet to granule formulation at our facility among patients with Crohn's disease in remission. We investigated the rate of continuous treatment of mesalazine granules and examined the changes in Crohn’s Disease Activity Index (CDAI) and serum C-reactive protein (CRP), albumin, and hemoglobin (Hb) levels 2 years after the switch. Compliance rate (continuous treatment vs. additional treatment) and continuous treatment rate [good (rate of ≥ 70%) vs. poor (rate < 70%)] were investigated. Of 46 patients, 12 (27.3%) received additional treatment and 32 (72.7%) did not require additional treatment in 2 years. No significant change in CDAI after switching to granule modification was noted in 32 patients in the continuous treatment group. Nevertheless, clinical remission was maintained for 2 years, and serum CRP levels decreased significantly (P = 0.023) and Hb levels increased significantly (P = 0.002). No change in the compliance rate was found. Our results suggest that mesalazine granule formulation may have a remission maintenance effect that is superior to that of mesalazine tablets.
format	article
author	Satoshi Tamura Natsuki Ishida Takahiro Miyazu Shunya Onoue Shinya Tani Mihoko Yamade Yasushi Hamaya Moriya Iwaizumi Satoshi Osawa Takahisa Furuta Ken Sugimoto
author_facet	Satoshi Tamura Natsuki Ishida Takahiro Miyazu Shunya Onoue Shinya Tani Mihoko Yamade Yasushi Hamaya Moriya Iwaizumi Satoshi Osawa Takahisa Furuta Ken Sugimoto
author_sort	Satoshi Tamura
title	Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
title_short	Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
title_full	Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
title_fullStr	Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
title_full_unstemmed	Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
title_sort	mesalazine granule formulation improves clinical data in crohn's disease compared with tablet formulation
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/51034e09db5b4b42b964b2e511743e39
work_keys_str_mv	AT satoshitamura mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT natsukiishida mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT takahiromiyazu mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT shunyaonoue mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT shinyatani mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT mihokoyamade mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT yasushihamaya mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT moriyaiwaizumi mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT satoshiosawa mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT takahisafuruta mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation AT kensugimoto mesalazinegranuleformulationimprovesclinicaldataincrohnsdiseasecomparedwithtabletformulation
_version_	1718384466743787520

Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation

Ejemplares similares